Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4924 Target Snapshot

Ribosomal protein S6 kinase alpha-6 · SINGLE PROTEIN · Homo sapiens

1,143Compounds
315Assays
12Approved Drugs
571.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9UK32. Use UniProt Q9UK32 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9UK32 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ribosomal protein S6 kinase alpha-6 as ChEMBL target CHEMBL4924, mapped to UniProt Q9UK32. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ribosomal protein S6 kinase alpha-6
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4924
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9UK32
Ribosomal protein S6 kinase alpha-6
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Ribosomal protein S6 kinase alpha-6 is the right protein anchor across sources, using UniProt Q9UK32 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRibosomal protein S6 kinase alpha-6
UniProt AccessionQ9UK32
Component TypeProtein
Sequence Length745 aa

Ribosomal protein S6 kinase alpha-6

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Ribosomal protein S6 kinase alpha-6, mapped to UniProt Q9UK32. Sequence length is 745 aa.

Mapped IDQ9UK32
Review nameRibosomal protein S6 kinase alpha-6
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

12
Approved
6
Phase III
10
Phase II
10
Phase I
Assay Mix

Activity Type Distribution

IC5082.0
KI1.0
KD488.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.99 IC50 0.102 Preclinical
CHEMBL5811142 9.52 IC50 0.3 Preclinical
CHEMBL4116008 8.4 IC50 4.0 Clinical
CHEMBL3128043 8.4 Kd 4.0 Preclinical
CHEMBL4543618 8.15 IC50 7.0 Preclinical
CHEMBL5786213 8.1 IC50 8.0 Preclinical
CHEMBL5816107 8.1 IC50 8.0 Preclinical
CHEMBL4847762 8.02 IC50 9.5 Preclinical
CHEMBL573107 8.0 IC50 10.0 Preclinical
CHEMBL4846725 7.92 IC50 12.0 Preclinical
Distribution

pChEMBL Value Distribution

26
5.0
33
5.5
21
6.0
21
6.5
7
7.0
20
7.5
7
8.0
0
8.5
0
9.0
5
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
TOFACITINIB CITRATE
CHEMBL2103743
Approved 2012
TOFACITINIB
CHEMBL221959
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
VANDETANIB
CHEMBL24828
Approved 2011
Assay Landscape

Assay Landscape

315
Total Assays
115
Tested Compounds
1
Assay Types
Binding — 315 assays, 115 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 251 73 6.5
assay format 40 1 4.8
cell-based format 18 21 6.1
subcellular format 6 20 6.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine